Are you wanting big returns for your portfolio? Then look no further!
That's because the ASX 200 shares listed below have been named as buys and tipped to rise by ~40%+ from current levels. Here's what analysts are predicting from them:
Neuren Pharmaceuticals Ltd (ASX: NEU)
Analysts at Bell Potter are very positive on this pharmaceuticals company. They believe that recent share price weakness has created an opportunity to buy the ASX 200 share at a very attractive level.
According to a note from last week, the broker has a buy rating and $25.00 price target on the company's shares. Based on its current share price of $14.19, this implies potential upside of 76% for investors over the next 12 months.
Bell Potter sees huge potential in the company's NNZ-2591 product, which is under development. It explains:
NEU is a biotech company that is well-funded via its first asset, DAYBUE, which is an FDA approved trofinetide for the treatment of Rett syndrome. NEU's value is from its second asset, NNZ-2591, which is under development for rare diseases. NNZ-2591, if successful, could lead to a significant increase in revenue and earnings when brought to market. NEU looks attractive on a risk/adjusted basis after the recent sell-off.
Treasury Wine Estates Ltd (ASX: TWE)
Over at Goldman Sachs, its analysts think that Treasury Wine could be an ASX 200 share to buy right now. Last week, Goldman put a buy rating and $15.20 price target on the wine giant's shares. Based on its current share price of $10.97, this implies potential upside of approximately 39% for investors.
Goldman believes that the company is well-positioned for growth in the coming years. Despite this, it notes that its shares trade on lower than average multiples. It said:
Our Buy rating on TWE is premised on accelerating double-digit EPS growth in FY24-27e driven by 1) continued global expansion of Penfolds, especially post the removal of China import tariffs on Australian wine; our recent channel checks suggest positive reception to the returning Australian sourced Penfolds and we expect a ~63pct pre-tariff recovery by 2027; and 2) its rank as the #1 luxury wine company in the US (most sales in luxury wine) with the recent acquisitions of Frank Family Vineyards (FFV) and DAOU which have been growth and margin accretive, combined with a stable portfolio of Premium Brands. TWE is trading modestly below the 5-year historical P/E average.
